The world's first joint diagnostic model for lung nodules "blood ctDNA methylation detection + CT image AI", KINDSTAR GLOBAL (09960)'s products lead the way in early screening and detection of lung cancer.

Since February, the medical field has welcomed good news. Various pharmaceutical companies have successively joined DeepSeek, Huawei's pathology big model, and other related AI models or made layouts in AI, hoping to infiltrate various aspects of the pharmaceutical field and empower pharmaceutical companies in an all-round manner. The leading specialty inspection company in China, KINDSTAR GLOBAL (09960), is leading the layout of AI diagnosis-related products. Its subsidiary, Benchmark Medical, launched the world's first joint analysis of lung nodules "blood ctDNA methylation detection + CT image AI" with the FeiYiJian PulmoSeek Plus product years ago. This product combines non-invasive liquid biopsy technology with CT imaging AI, which can be used for differential diagnosis of benign and malignant lung nodules, follow-up management, and prediction of the degree of infiltration of pulmonary adenocarcinoma in high-risk nodules before surgery. As a First-in-Class product in the field of cancer early screening and early diagnosis, based on CT/LDCT imaging DICOM data, it measures nearly a hundred imaging (groups) related parameters of the nodules, identifies and extracts relevant signs, matches 4000+ cases of pathological diagnosis, and 40,000 to 60,000 cases of "4D" imaging data, assisting doctors in identifying the nature of lung nodules and predicting the degree of infiltration of pulmonary adenocarcinoma in high-risk lung nodules. As the first international multimodal diagnostic model developed using a combination of cfDNA methylation biomarkers, clinical information, and imaging features for machine learning modeling, PulmoSeek Plus is used for differential diagnosis of benign and malignant lung nodules, and assists in the management of uncertain nodules. Research findings have been published in the Journal of Clinical Investigation (2022 IF=15.9) and The Lancet Digital Health (2022 IF=30.8). In the 2023 edition of the "Chinese Expert Consensus on Early Lung Cancer Diagnosis," PulmoSeek has been recommended for non-invasive auxiliary diagnosis of early lung cancer, and has also obtained CE Mark certification and ISO13485:2016 international certification overseas. In clinical practice, FeiYiJian has conducted a large-scale research project on early screening and early diagnosis of lung cancer with multinational pharmaceutical companies. It has also cooperated with the Johnson Lung Cancer Center for four years, selecting at least 3,000 eligible patients with lung nodules, collecting blood and tissue samples, CT/LDCT imaging data, and pathology information. In the domestic field, Benchmark Medical has also cooperated with many centers such as the First Affiliated Hospital of Guangzhou Medical University, and has accumulated nearly 4000 cases in the study. According to Frost & Sullivan, the market size of the AI medical industry in China is expected to grow rapidly. The market size of the AI medical market in China is expected to increase from 8.8 billion yuan in 2023 to 315.7 billion yuan in 2033, with a compound annual growth rate of 43.1% from 2023 to 2033. In terms of policies, both the central and local governments attach great importance to the development of artificial intelligence + medical care, and related policy documents are being intensively introduced. In November 2024, the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Health Commission developed the "Reference Guide for the Application Scenarios of Artificial Intelligence in the Health Industry," listing 84 innovative applications of AI in the medical field, including AI + pharmaceuticals, AI + medical insurance, AI + health management, AI + medical services, etc. In the same month, the National Medical Insurance Administration first included AI-assisted diagnosis in the project guidelines, and AI-assisted diagnosis was first included in the medical insurance. With the continuous improvement of large models and policy support, it is believed that industry leaders who have laid out in the AI field early will continue to benefit from forward-looking proactive strategies, discover more new ecosystems for the future of the entire medical and health industry, and explore more industry opportunities.